profit from every $100 of sales.
$0$100
Bright Minds Biosciences
$22.74-3.03% today
-62.2% in 1 year
1-year low $18.961-year high $95.99
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bright Minds Biosciences sold, what it kept, and what it did with the cash.
Sales went from CA$0 in 2022 to CA$0 in 2025, with -CA$12.2 million of profit last year.
SalesProfit
Bright Minds Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bright Minds Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Bright Minds Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -15 | -7 | -3 | -14 | |
| -15 | -7 | -3 | -14 | |
| -15 | -7 | -3 | -12 | |
| -6.06 | -1.98 | -0.65 | -1.78 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 12 | 7 | 6 | 84 |
| Cash | 12 | 7 | 6 | 83 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 2 | 0 | 1 | 2 |
| 11 | 7 | 6 | 82 | |
| 2 | 4 | 4 | 7 | |
| -110.7% | -87.5% | -39.4% | -13.4% | |
| -141.9% | -111.7% | -50.6% | -14.9% |
Cash flow
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -14 | -7 | -2 | -9 | |
| – | – | – | – | |
| -14 | -7 | -2 | -9 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 3 |
Valuation
- –
- –
- –
- 10.2×
- –
- –
- –
- -2.7%
- -3.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -21.5%
- -71.9%
- -28.5%
- -21.8%
- -21.5%
- –
Growth
- –
- –
- −369.8%
- –
- +39.9%
Financial health
- 4.6×
- 0.00
- 0.1%
- -2,633.9×
- 57.37
- 57.37
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 952
Bottom 20%of 883
Bottom 26%of 985
What analysts expect
- Average price target
- $136.50
- Range
- $126.00 – $147.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 12, 2026 | -0.70 | -0.98 | +28.6% |
| Dec 23, 2025 | -0.41 | -0.56 | +27.1% |
| Aug 14, 2025 | -0.53 | -0.59 | +10.2% |
| Feb 13, 2025 | 0.01 | -0.23 | +104.3% |
| Dec 30, 2024 | -0.12 | -0.44 | +72.9% |
| Aug 14, 2024 | 0.04 | – | – |
| May 15, 2024 | -0.10 | – | – |
| Feb 12, 2024 | -0.32 | – | – |
News
A failed trial for a heart drug casts shadow over rivals developing similar therapiesMarketWatch · Nov 9, 2026AbbVie reports improved facial satisfaction among weight-loss drug usersSeeking Alpha · Nov 9, 2026J&J reports patient findings from Sjögren’s drug studySeeking Alpha · Nov 8, 2026Arrowhead reports lower pancreatitis rates, early cholesterol drug resultsSeeking Alpha · Nov 8, 2026Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?Yahoo Finance · Nov 8, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
14No pass
Benjamin Graham
25No pass
Philip Fisher
27No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
16No pass
Terry Smith
10No pass
Questions about Bright Minds Biosciences
Is Bright Minds Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bright Minds Biosciences AI analysis
What does Bright Minds Biosciences do?
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. It is in Biotechnology.
Does Bright Minds Biosciences pay a dividend?
No. Bright Minds Biosciences does not pay a dividend at the moment.
Is Bright Minds Biosciences stock halal?
Yes. Bright Minds Biosciences passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Bright Minds Biosciences stock done over the past year?
Down 62.2% over the past twelve months, to $22.74. It traded between $18.96 and $95.99 and is 76.3% below its high.
Who are Bright Minds Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Bright Minds Biosciences's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.